Scientific publication by AdaptVac researchers about a capsid virus-like particle-based vaccine targeting IL-1β for treatment of allergic contact dermatitis
Hørsholm, Denmark, May 25, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the scientific journal Vaccines published an article authored by AdaptVac researchers about a capsid virus-like particle-based vaccine targeting IL-1β for treatment of allergic contact dermatitis.
Excerpt: “…the data suggest that a cVLP-based vaccine displaying full-length IL-1β represents a promising vaccine candidate for use as an alternative treatment modality against severe ACD.”
The scientific article is titled “Preclinical Efficacy of a Capsid Virus-Like Particle-Based Vaccine Targeting IL-1β for Treatment of Allergic Contact Dermatitis”. Paper reference: Goksøyr, L. et al., Vaccines 2022, 10, 828. https://doi.org/10.3390/vaccines10050828. The article can also be found via this link.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.